Behavioral treatments such as relaxation training, hypnosis and biofeedback to help prevent chronic migraine headaches are cost-effective alternatives to prescription drugs, a new study suggests.
Researchers compared the costs of several types of behavioral treatment with preventive prescription drugs. After six months, minimal-contact behavioral treatment was comparable with drug treatment using medicines that cost 50 cents or less per day.
In minimal-contact treatment, a patient sees a therapist a few times a year and for the most part practices the behavioral techniques at home, helped by literature or audio tapes.
After one year, minimal-contact therapy was nearly $500 cheaper than drug treatment.
The study is published in the June issue of the journal Headache.
Initially, the daily cost of prescription drugs taken as a preventive measure by many chronic migraine sufferers may not seem too high, said study co-author Dr. Donald Penzien, a professor of psychiatry at the University of Mississippi Medical Center.
"But those costs keep adding up with additional doctor visits and more prescriptions. The cost of behavioral treatment is front-loaded. You go to a number of treatment sessions but then that's it. And the benefits last for years," he said in a medical center news release.
SOURCE: University of Mississippi Medical Center, news release, July 5, 2011
Medical and health related news to check and see if his students still listen and do no harm.
News from Mayo Clinic
- Mayo Clinic Q and A: Colorectal cancer in young adults - 3/31/2025
- A clearer path through a difficult diagnosis - 3/28/2025
- Advancing medicine one lab test at a time - 3/26/2025
- Mayo Clinic Laboratories and Amprion announce collaboration to advance neurodegenerative disease diagnostics - 3/26/2025
- Dr. Eric Moore appointed medical director, International at Mayo Clinic - 3/26/2025
THE "NEW" PROSTATE CANCER INFOLINK
- Active surveillance: a future perspective
- NCCN guidance on initial management of low-risk, localized prostate cancer (redux)
- Projected attendance at AS research conference
- Registration for major active surveillance (AS) research conference now open
- NCCN guidance on the initial management of low-risk, localized prostate cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment